Rheumatology Practice Management June 2017 Vol 5 No 3
The National Organization of Rheumatology Managers (NORM) is pleased to announce that we have joined forces with several patient and provider groups, including the Coalition of State Rheumatology Organizations (CSRO), the American College of Rheumatology, the Global Healthy Living Foundation, the Rheumatology Nurses Society, and the Arthritis Foundation (AF) to form the Alliance for Transparent and Affordable Prescriptions (ATAP).
“Incident to” services are defined as services that are furnished incident to physician professional services in the physician’s office. These services are paid at 100% of the physician fee schedule, whereas services reported by nonphysician practitioners are paid at 85%.
The National Organization of Rheumatology Managers (NORM) is proud to offer our 2017 Annual Conference, September 14 - 16, in Kansas City, MO. Our expert speakers and educational sessions will help you further develop your management skills and lead your practice successfully into the future.
“The Administration’s proposed 2018 budget would slash vital funding for institutions and agencies that, together with rheumatology providers, are on the frontlines of rheumatic disease prevention and care."
Final Report by Institute for Clinical and Economic Review Raises Concerns in the Rheumatology Community
On January 20, 2017, the Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report evaluating the clinical effectiveness and relative value—including value-based price benchmarks—of targeted immune modulators used to treat patients with moderate-to-severe rheumatoid arthritis (RA).
Your provider is out of town attending a medical convention, but one of his partners is in the office. Is the visit with the nurse practitioner eligible for incident-to billing?
New Treatments Approved for Patients with Giant-Cell Arteritis and Moderate-to- Severe Rheumatoid Arthritis
Tocilizumab is the first therapy approved by the FDA for the treatment of adult patients with this type of vasculitis, and was granted Breakthrough Therapy designation and Priority Review for this indication.
Dr Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs, and as Senior Advisor to the FDA Commissioner.
The following clinical trials represent a selection of key studies that are currently recruiting patients with fibromyalgia for inclusion in investigations of new therapies and new regimens of existing treatments for individuals with the disease.
Results 1 - 9 of 9